PI3K mutations in breast cancer: prognostic and therapeutic implications.

Pertuzumab A biomarker study associated with the TRYPHAENA study, a randomized Phase II study comparing three treatment arms involving pertuzumab and trastuzumab in combination with chemotherapy, showed that patients carrying PIK3CA mutations tended to have a lower p-CR rate compared to patients with wild-type PIK3CA , although the difference did not reach statistical significance. 59 This finding indicates that the addition of pertuzumab may not be sufficient to overcome trastuzumab resistance caused by PIK3CA mutations.

also in 111,027 other papers